A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Conditions: Colorectal Cancer Metastatic; Triple Negative Breast Cancer; Non Small Cell Lung Cancer; Bladder Cancer; GastroEsophageal Cancer; Renal Cell Carcinoma; MSI-H Interventions: Biological: EDP1503; Biological: Pembrolizumab Sponsors: Evelo Biosciences, Inc.; SCRI Development Innovations, LLC; Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Gastroenterology | Research | Study